|
|
|||||||
Bone Marrow Failure |
Department of Haematological Medicine, Leukaemia Sciences Laboratories, The Rayne Institute, Kings College London, Denmark Hill Campus, London, UK
Correspondence: Ghulam J. Mufti, Department of Haematological Medicine, Kings College London, The Rayne Institute, 123 Coldharbour Lane, London SE5 9NU, UK. E-mail:ghulam.mufti{at}kcl.ac.uk
Poly ADP-ribose polymerase inhibitors have been shown to target cells with homologous recombination DNA repair defects. We report that poly ADP-ribose polymerase inhibitors induces apoptosis in cells deficient in other key DNA repair components. Chromosomal instability disorders, Fanconi Anemia and Blooms syndrome have dysfunctional DNA repair and an increased likelihood of leukemic transformation. PI addition to Fanconi Anemia and Blooms syndrome cells resulted in significant apoptosis. Furthermore, poly ADP-ribose polymerase inhibitors induced apoptosis in DNA repair signaling defective ATM–/– and NBS–/– fibroblasts. Immunocytochemistry showed homologous recombination was abrogated in NBS–/– and ATM–/– fibroblasts, compromised in Fanconi anemia and normal in Blooms syndrome cells in response to poly ADP-ribose polymerase inhibitors. Strikingly, poly ADP-ribose polymerase inhibitors increases non-homologous end joining repair activity, whilst non-homologous end joining deficient cells are extremely sensitive to poly ADP-ribose polymerase inhibitors. These data suggest poly ADP-ribose polymerase inhibitors target cells with DNA repair and signaling defects rather than solely defects in homologous recombination improving the potential of poly ADP-ribose polymerase inhibitors therapy in a wider range of cancers.
Key words: Poly ADP-ribose polymerase, leukemia, DNA repair.
This article has been cited by other articles:
![]() |
T. J. Gaymes, S. Shall, L. J. MacPherson, N. A. Twine, N. C. Lea, F. Farzaneh, and G. J. Mufti Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes Haematologica, May 1, 2009; 94(5): 638 - 646. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | TABLE OF CONTENTS | ARCHIVE | SUBSCRIPTIONS |